Why the study?
The National Lipid Association's Muscle Safety Expert Panel was charged with examining definitions for statin-associated muscle adverse events, developing a clinical index for myalgia, and providing guidance on neuromuscular studies and treatment algorithms for statin-intolerant patients.
Provides expert consensus definitions, a clinical myalgia index, and a management algorithm for evaluating and treating patients with statin-associated muscle symptoms.
Answers are grounded in this paper and cite their sources.
Guides statin muscle symptom evaluation in practice; leaves open optimal diagnostic and management strategies pending higher-level trials.
The National Lipid Association's Muscle Safety Expert Panel was charged with the duty of examining the definitions for statin-associated muscle adverse events, development of a clinical index to assess myalgia, and the use of diagnostic neuromuscular studies to investigate muscle adverse events. We provide guidance as to when a patient should be considered for referral to neuromuscular specialists and indications for the performance of a skeletal muscle biopsy. Based on this review of evidence, we developed an algorithm for the evaluation and treatment of patients who may be intolerant to statins as the result of adverse muscle events. The panel was composed of clinical cardiologists, clinical lipidologists, an exercise physiologist, and a neuromuscular specialist.
No takes yet. Share an insight, caveat, or question.
Rosenson et al. (2014) conducted a review in Statin-associated muscle adverse events / statin intolerance. Statin therapy and clinical evaluation/treatment algorithm for muscle adverse events was evaluated. The National Lipid Association's Muscle Safety Expert Panel developed definitions, a myalgia clinical index, and an evaluation and treatment algorithm for statin-associated muscle adverse events.
Synapse has enriched 10 related papers. Consider them for comparative context: